CooleyREG Talks:
US Election Implications
Session 3: Election Implications for the Life Sciences Sector
Event summary
With the new administration ushering in potential shifts in healthcare policy and regulatory oversight, this session will focus on anticipated changes for the life sciences industry, including potential enforcement discretion policies that could impact existing rules and enforcement priorities at the Food and Drug Administration (FDA), Federal Trade Commission (FTC) and other federal agencies. Learn how to strategically position your business amid an evolving regulatory landscape.
Presenters
- Alexis Bortniker – Cooley partner
- Megan Browdie – Cooley partner
- Phil Mitchell – Cooley partner
- Sonia Nath – Cooley partner and former senior counsel, FDA
- Son Nguyen – Cooley special counsel and former senior counsel, FDA
- Vince Sampson – Cooley special counsel and former congressional and executive branch senior staff member
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.